Literature DB >> 23378551

Boston keratoprosthesis for visual rehabilitation in porphyria cutanea tarda.

Alok Sati1, Virender S Sangwan, Sayan Basu, Parthasarathi Kalaiselvan.   

Abstract

A 56-year-old man, presented with bilateral chronic visual loss associated with generalised skin lesions. He had undergone multiple penetrating keratoplasties in his right eye for recurrent corneal infections and perforations. On ocular examination, his left eye was phthisical and his right eye had light perception vision owing to a failed and vascularised corneal graft. Dermatological evaluation revealed multiple hyperpigmented and hypopigmented lesions along with thickening of skin on nose, scalp and dorsum of hands. Skin biopsy showed focal areas of deposition of faint periodic acid Schiff-positive diastase-resistant perivascular material. The high-performance liquid chromatography assessment revealed increased presence of porphyrins in blood and urine, thus confirming a diagnosis of porphyria cutanea tarda. The patient's vision in the right eye improved after undergoing Boston type 1 keratoprosthesis along with general photoprotective measures for the exposed parts of the body.

Entities:  

Mesh:

Year:  2013        PMID: 23378551      PMCID: PMC3603872          DOI: 10.1136/bcr-2012-008267

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Congenital porphyria with necrotizing scleritis in a 9-year-old child.

Authors:  P Venkatesh; S P Garg; E Kumaran; H K Tewari
Journal:  Clin Exp Ophthalmol       Date:  2000-08       Impact factor: 4.207

2.  Photodamage of the conjunctiva in patients with porphyria cutanea tarda.

Authors:  H Hammer; I Korom
Journal:  Br J Ophthalmol       Date:  1992-10       Impact factor: 4.638

3.  Sight threatening complications in porphyria cutanea tarda.

Authors:  A G Zaborowski; G H Paulson; A L Peters
Journal:  Eye (Lond)       Date:  2004-09       Impact factor: 3.775

4.  Porphyria cutanea tarda.

Authors:  Patrick Yachimski; Nirali Shah; Raymond T Chung
Journal:  Clin Gastroenterol Hepatol       Date:  2007-02       Impact factor: 11.382

Review 5.  Psoriasis, ichthyosis, and porphyria.

Authors:  G Steiner; R C Arffa
Journal:  Int Ophthalmol Clin       Date:  1997

6.  Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients.

Authors:  M E Grossman; D R Bickers; M B Poh-Fitzpatrick; V A Deleo; L C Harber
Journal:  Am J Med       Date:  1979-08       Impact factor: 4.965

7.  Cicatricial ectropion and lacrimal obstruction associated with the sclerodermoid variant of porphyria cutanea tarda.

Authors:  A J Sober; A S Grove; J E Muhlbauer
Journal:  Am J Ophthalmol       Date:  1981-03       Impact factor: 5.258

8.  Scleral necrosis in a patient with congenital erythropoietic porphyria.

Authors:  Sana S Siddique; Luis A Gonzalez-Gonzalez; Pranjal Thakuria; Peter Y Chang; C Stephen Foster
Journal:  Cornea       Date:  2011-01       Impact factor: 2.651

9.  International results with the Boston type I keratoprosthesis.

Authors:  Anthony J Aldave; Virender S Sangwan; Sayan Basu; Samar K Basak; Anna Hovakimyan; Ofelya Gevorgyan; Soliman Al Kharashi; Mohanna Al Jindan; Radhika Tandon; Jeena Mascarenhas; Boris Malyugin; Ma Dominga B Padilla; Quresh Maskati; Nisheeta Agarwala; Johan Hutauruk; Manoj Sharma; Fei Yu
Journal:  Ophthalmology       Date:  2012-04-17       Impact factor: 12.079

10.  Acute scleritis as a manifestation of congenital erythropoietic porphyria.

Authors:  M P Veenashree; Virender S Sangwan; Geeta K Vemuganti; Anchala Parthasaradhi
Journal:  Cornea       Date:  2002-07       Impact factor: 2.651

View more
  2 in total

1.  Porphyria: varied ocular manifestations and management.

Authors:  Alok Sati; Virender S Sangwan; Sayan Basu
Journal:  BMJ Case Rep       Date:  2013-05-22

2.  Ocular manifestations in patient with congenital erythropoietic porphyria.

Authors:  C Isanta-Otal; G López-Valverde; A J Mateo Orobia; L E Pablo
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.